retatrutide triumph TRIUMPH-4: Beat Every Prediction (Full Data) Lilly's Retatrutide Scores Triple Trial

There are now four proven therapies that can reduce the risk of kidney disease progression in people with type 2 diabetes: reninangiotensinaldosterone system (RAAS) blockade, with either ACE inhibitors or angiotensin receptor blockers (ARBs) sodium-glucose cotransporter-2 (SGLT-2) inhibitors nonsteroidal mineralocorticoid receptor antagonists (MRAs) glucagon-like peptide-1 (GLP-1) receptor agonists

With the 2026 expansion of Foundayo and Wegovy production, the prior shortages that drove compounded use are largely resolved

Due to this rapid degradation, endogenous GLP-1 secreted from the gut must exert its biological effects immediately upon release

M., & Spencer, R